Efficacy of platinum plus cyclophosphamide in patients with epithelial ovarian cancer

Journal of the Medical Association of Thailand

Volumn 88, Issue 9, 2005, Pages 1172-1181

  Tangjitgamol, Siriwan ^a   Mamusirinitaya, Sumonmal ^a   Leelahakorn, Surawute ^a   Thawaramara, Thaowalai ^a   Pataradool, Kamol ^a   Suekwatana, Pacheun ^a   Sittidilokratna, Kriengkrai ^a  

^a Bangkok Metropolitan Administration   (Thailand)

Author keywords

Cyclophosphamide; Epithelial ovarian cancer; Platinum; Response rate; Survival rate

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; PLATINUM;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CYTOREDUCTIVE SURGERY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HOSPITAL ADMISSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; RECURRENT DISEASE; REVIEW; SURVIVAL RATE; TIME SERIES ANALYSIS;

ADULT; AGED; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 31544454426     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Vatanasapt V, Martin N, Sriplung H, Chindavijak K, Sontipong S, Sriamporn H, et al. Cancer in Thailand 1988-1991. IARC technical report No. 166, Lyon: International Agency for Research on Cancer, 1993.
2. Gershenson DM, Wharton JT. Surgery for ovarian cancer. In: Gershenson DM, De Cherney AH, Curry SL, editors. Operative gynecology. Philadelphia: WB Saunders, 1993: 523-47.
3. Young RC, MF Brady, RM Nieberg, Long HJ, Mayer AR, Lent Hurteau J, et al. Adjuvant treatment of early ovarian cancer. Randomized phase III trial of intraperitoneal 32 P or intravenous cyclophosphamide and cisplatin -a gynecologic oncology group study. J Clin Oncol 2003; 21: 4350-5.
4. Gershenson DM, Copeland LJ, Wharton JT, Stringer CA, Edwards CL, Kavanagh JJ, et al. Treatment of advanced epithelial ovarian cancer with cisplatin and cyclophosphamide. N Engl J Med 1987; 10: 336-41.
5. Decker DG, Fleming TR, Malkasian GD Jr, Webb MJ, Jeffries JA, Edmonson JH. Cyclophosphamide plus cis-platinum in combination: treatment program for stage III or IV ovarian carcinoma. Obstet Gynecol 1982; 60: 481-7.
6. Conte PF, Bruzzone M, Chiara S, Sertoli MR, Daga MG, Rubagotti A, et al. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer. Aust N Z J Med 1982; 12: 245-9.
7. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
8. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, et al. Ramdomized intergroup trial of cisplatin and paclitaxel versus cyclophosphamide and cisplatin in woman with advanced epithelial ovarian cancer: Three-years result. J Natl Cancer Inst 2000; 92: 699-708.
9. Ozols RF, Bundy BN, Greer BE, Fowler JF, Pearson DC, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer. J Clin Oncol 2003; 21: 3194-200.
10. Guidelines for the management of ovarian cancer 2003-2004. The study committee for gynecologic malignancy. The Royal Thai College of Obstetricians and Gynecologists. 2003: 51.
11. Manual drugs' price lists. Bangkok Metropolitan Medical College and Vajira Hospital, 2004.
12. Benedet JL, Bender H, Jones H III, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynecol Obstet 2000; 70: 209-62.
13. Gelber RD, Zelen M. Planning and reporting of clinical trials. In: Calabresi P, Schen PS, editors. Medical oncology: principle and clinical management of cancer. 2 nd ed. New York: Mc Graw Hill, 1993: 383-400.
14. Aabo K, Adams M, Adnitt P, Alberts DS, Athanazziou A, Barley V, et al. Chemotherapy in advanced ovarian cancer: four systematic metaanalyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer 1998; 78: 1479-87.
15. Alberts DS, Green S, Hanningan EV, O' Toole R, Anderson P, Surwit EA, et al. Improved therapeutic index of carboplatin plus cyclophosphamide vs cisplatin plus cyclophosphamide: Final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 1992; 10: 706-17.
16. Swenerton K, Jeffrey J, Stuart G, Roy M, Krepart G, Carmichaei J, et al. Cisplatin-cyclophosphamide vs carboplatin-cyclophosphamide in advanced ovarian cancer: A randomized phase III study of National Cancer Institute of Canada Clinical Trial Group. J Clin Oncol 1992; 10: 718-26.
17. Linasmita V, Wilailuk S, Srisupundir S, Tangtrakul S, Bullangpoti S, Israngura N. Epithelial ovarian cancer treated by platinum or platinum analogue with cyclophosphamide: experience in Ramathibodi Hospital. J Med Assoc Thai 1998; 81: 10-6.
18. Neijt JP, ten Bokkel Huinink WW, van der Burg ME, van Oosterom AT, Willemse PH, Heintz AP, et al. Randomized trial comparing two combination chemotherapy regimens CHAP-5 v CP in advanced ovarian carcinoma. J Clin Oncol 1987; 5: 1157-68.
19. Thirapakawong C, Neungton S, Senapad S, Mekariya S, Vichaithum K, Srisomboon J. Randomized trial of paclitaxel plus paraplatin versus cyclophosphamide plus paraplatin in the treatment of advanced epithelial ovarian cancer. Thai J Obstet Gynaecol 2000; 12: 295-302.